Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis.

Retrovirology
Qi ZhengJ Gerardo García-Lerma

Abstract

Pre-exposure prophylaxis (PrEP) with daily Truvada [a combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)] is a novel HIV prevention strategy recently found to prevent HIV transmission among men who have sex with men and heterosexual couples. Acute infection in adherent persons who fail PrEP will inevitably occur under concurrent antiretroviral therapy, thus raising questions regarding the potential impact of PrEP on early viral dynamics. We investigated viral evolution dynamics in a macaque model of PrEP consisting of repeated rectal exposures to SHIV162P3 in the presence of PrEP. Four macaques were infected during daily or intermittent PrEP with FTC or FTC/TDF, and five were untreated controls. SHIV env sequence evolution was monitored by single genome amplification with phylogenetic and sequence analysis. Mean nucleotide divergence from transmitted founder viruses calculated 17 weeks (range = 12-20) post peak viremia was significantly lower in PrEP failures than in control animals (7.2 × 10-3 compared to 1.6 × 10-2 nucleotide substitutions per site per year, respectively, p < 0.0001). Mean virus diversity was also lower in PrEP failures after 17 weeks (0.13% vs. 0.53% in controls, p < 0.0001). Our resu...Continue Reading

References

Jul 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·Koichiro TamuraSudhir Kumar
May 10, 2007·Molecular Biology and Evolution·Koichiro TamuraSudhir Kumar
Jun 1, 2007·Journal of Virology·John T LoffredoDavid I Watkins
May 21, 2008·Proceedings of the National Academy of Sciences of the United States of America·Brandon F KeeleGeorge M Shaw
Dec 8, 2009·Trends in Pharmacological Sciences·J Gerardo García-LermaWalid Heneine
Apr 8, 2010·Science Translational Medicine·J Gerardo García-LermaWalid Heneine
May 21, 2010·PLoS Pathogens·Hui LiGeorge M Shaw
Jul 14, 2010·Journal of Medical Primatology·James M SmithRon A Otten
Sep 25, 2010·The Journal of Infectious Diseases·Christian L BoutwellTodd M Allen
Nov 26, 2010·The New England Journal of Medicine·Robert M GrantUNKNOWN iPrEx Study Team
Jun 4, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Kelly A CurtisJ Gerardo García-Lerma

❮ Previous
Next ❯

Citations

Jun 29, 2012·The Journal of Infectious Diseases·Ellen N KershJ Gerardo Garcia-Lerma
Sep 24, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Nigel J GarrettSalim S Abdool-Karim
May 15, 2013·Current Opinion in HIV and AIDS·Christine M Fennessey, Brandon F Keele
Sep 12, 2012·Current Opinion in HIV and AIDS·J Gerardo García-Lerma, Walid Heneine
May 24, 2013·Current Opinion in HIV and AIDS·Ronald S Veazey
Dec 15, 2020·The Lancet. HIV·Juan AmbrosioniJosé M Miró

❮ Previous
Next ❯

Datasets Mentioned

BETA
AF536757
EU123924

Methods Mentioned

BETA
SGA
PCR
glycosylation

Software Mentioned

geno2pheno co - receptor
SGA
Editor
Vector NTI Advance
GlycoSite
MEGA
MEGA5
Geno2pheno
Highlighter
GraphPad Prism

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.